New drug combo takes on Hard-to-Treat KRAS cancers

NCT ID NCT04111458

Ongoing Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jan 12, 2026 · Last updated May 21, 2026 · Updated 24 times

Summary

This early-phase study tests a new experimental drug, BI 1701963, that blocks a cancer-driving protein called KRAS. It is given alone or with an approved drug, trametinib, to adults with advanced solid tumors that have a KRAS mutation and have stopped responding to standard treatments. The main goals are to find the highest safe dose and to see if the combination can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS, KRAS MUTATION; SOS1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Erasmus Medisch Centrum-ROTTERDAM-50697

Rotterdam, 3015 GD, Netherlands
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Sarah Cannon Research Institute-Nashville-48456

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Universitair Medisch Centrum Utrecht

Utrecht, 3584 CX, Netherlands
Universitätsklinikum Frankfurt

Frankfurt am Main, 60590, Germany
Universitätsklinikum Köln (AöR)

Cologne, 50937, Germany

Conditions

Explore the condition pages connected to this study.

SOLID TUMORS, KRAS MUTATION; SOS1